# Glyconics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glyconics

- Industry: Medical Devices & Equipment
- Headquarters: Norwich, UK
- Website: www.glyconics.com
- Latest round: Seed (Apr 1, 2015)
- Investors on record: 1

## About

Glyconics Ltd is a technology company focused on developing innovative solutions for diabetes screening, offering advanced diagnostic tools to improve patient outcomes and healthcare efficiency.Founded in 2013 and headquartered in Norwich, UK, Glyconics Ltd is dedicated to advancing diabetes treatment through its innovative screening tools. The company has secured four investment deals, with the most recent funding round occurring on November 18, 2021, where they raised GBP 1.55 million led by Wealth Club, along with participation from Boundary Capital and Deepbridge Capital, bringing the total amount raised to GBP 1.55 million with a current valuation of GBP 5.85 million. The CEO, Kam Pooni, has played a pivotal role in guiding the company’s mission and strategy.Glyconics Ltd specializes in providing advanced technological solutions that enhance diabetes screening through their flagship product, the Glyconics-SX™ point-of-care tool. This innovative solution is designed to streamline operational processes in healthcare settings, enabling accurate and efficient diabetes screening. Their offerings primarily cater to healthcare providers across North America, Europe, and parts of Asia, focusing on critical applications such as patient identification, diagnosis, and care management.Glyconics Ltd operates on a subscription-based revenue model, where clients engage in annual or monthly agreements to access their suite of diabetes screening products. This model ensures continuous service delivery, including software updates and customer support, enhancing the overall value for healthcare providers. The company also seeks partnership agreements to strengthen its market presence, with pricing plans tailored to accommodate varying client needs.Following the GBP 1.55 million funding round on November 18, 2021, Glyconics Ltd plans to utilize the capital to conduct a large-scale trial program for its Glyconics-SX™ diabetes screening tool, which is essential for regulatory approval and CE marking. The company aims to expand its market reach into new regions and bolster its product offerings, with expectations for a Series A round in the upcoming year.

## Funding rounds

- Seed, Apr 1, 2015 — Deepbridge Capital

## Investors

- Deepbridge Capital (https://capitalatlas.ai/funds/deepbridge-capital) — Seed